Literature DB >> 7057187

On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain.

B H Westerink, S J Spaan.   

Abstract

3-Methoxytyramine (3-MT) was measured in the striata of rats killed by microwave radiation. Apomorphine, gamma-butyrolactone (GBL), and reserpine decreased the 3-MT content. A slight but transient increase in 3-MT was observed after haloperidol. The turnover rate of 3-MT was unchanged 60 min after haloperidol treatment. (+)-Amphetamine induced a pronounced rise in the 3-MT content, which was potentiated after combined treatment with haloperidol. The increased 3-MT turnover rate that was observed after amphetamine treatment suggests that monoamine oxidase (MAO) inhibition is no explanation for the mechanism of interaction of this drug with dopamine (DA) metabolism. The central stimulants amphonelic acid and nomifensine increased 3-MT levels; no substantial change was seen after benztropine, morphine, or oxotremorine. It is concluded that a decreased release of DA is closely and rapidly reflected by decreased formation of 3-MT. 3-MT seems to be a much better indicator for decreased DA release than 3,4-dihydroxyphenylacetic acid or homovanillic acid.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7057187     DOI: 10.1111/j.1471-4159.1982.tb08685.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

1.  Distribution of dopamine, its metabolites, and D1 and D2 receptors in heterozygous and homozygous weaver mutant mice.

Authors:  T A Reader; A R Ase; C Hébert; F Amdiss
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

2.  Regulatory aspects of nigrostriatal dopaminergic neurons.

Authors:  P Miu; F Karoum; G Toffano; J W Commissiong
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

3.  In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine.

Authors:  B A Bailey; S R Philips; A A Boulton
Journal:  Neurochem Res       Date:  1987-02       Impact factor: 3.996

Review 4.  Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine.

Authors:  M F Egan; S Chrapusta; F Karoum; B K Lipska; R J Wyatt
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Analysis of cat retina for dopamine, dihydroxyphenylacetic acid, 3-methoxytyramine and homovanillic acid.

Authors:  D M Vaughn; D M Lindley; N R Cox; S T Simpson; W L Whitmer
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

6.  Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.

Authors:  M I Colado; E O'Shea; R Granados; B Esteban; A B Martín; A R Green
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

7.  Withdrawal from repeated morphine sensitizes mice to the striatal dopamine release enhancing effect of acute morphine.

Authors:  J Airio; M Attila; T Leikola-Pelho; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

8.  The dopamine metabolite 3-methoxytyramine is a neuromodulator.

Authors:  Tatyana D Sotnikova; Jean-Martin Beaulieu; Stefano Espinoza; Bernard Masri; Xiaodong Zhang; Ali Salahpour; Larry S Barak; Marc G Caron; Raul R Gainetdinov
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

9.  Antagonism of the nicotine-induced changes of the striatal dopamine metabolism in mice by mecamylamine and pempidine.

Authors:  H Haikala; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

10.  The release of endogenous dopamine and its metabolites from rat striatum as detected in push-pull perfusates: effects of systematically administered drugs.

Authors:  F S Radhakishun; J Korf; K Venema; B H Westerink
Journal:  Pharm Weekbl Sci       Date:  1983-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.